Auritec Pharmaceuticals LLC (AKA: Auritec Pharma~Auritec Pharmaceuticals LLC) Profile last edited on: 4/30/2018
CAGE: 414W4
UEI: QX8KP6JKQ2L8
Business Identifier: Sustained Release Drug Delivery 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
1512 11th Street Suite 203
Santa Monica, CA 90401
Santa Monica, CA 90401
| (310) 434-0185 |
| mblake@auritecpharma.com |
| www.auritecpharma.com |
Location: Multiple
Congr. District: 36
County: Los Angeles
Congr. District: 36
County: Los Angeles
Public Profile
Auritec Pharmaceuticals LLC is developing extended release drug delivery systems, with applications in treating a variety of life-threatening diseases. The company's proprietary Plexis technology combines a membrane-based, diffusion-driven release mechanism with drug particle sizing large enough to allow high drug loading but small enough to be injected. Auritec's Versa platform involves a core of a solid drug coated with a semi-permeable polymer-targeted and sustained drug delivery system. The Plexis platform may be used in the treatment of schizophrenia, Alzheimers, graft rejection, arthritis, macular edema and HIV. Auritecs Versa platform utilizes the technology behind the FDA approved Vitrasert and Retisert for sustained release implants of a wide range of solubilities over the timescale of months to years.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
15-19Revenue Range
1.5M-2MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
10-14Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2023 | 2 | NIH | $4,161,751 | |
| Project Title: Preclinical Development of an Intravaginal Ring for the Sustained Release of Pritelivir for the Treatment and Prophylaxis of Genital Herpes in Women | ||||
| 2023 | 2 | NIH | $2,047,614 | |
| Project Title: Long-acting injectable tacrolimus for chronic immunosuppression | ||||
| 2022 | 2 | NIH | $1,999,278 | |
| Project Title: Longer-Acting Intravaginal Formulation of Buprenorphine | ||||
| 2020 | 2 | NIH | $2,219,320 | |
| Project Title: Preclinical Development of a Multipurpose Intravaginal Ring for the Prevention of HIV and Unintended Pregnancy | ||||
| 2017 | 2 | NIH | $2,784,147 | |
| Project Title: Sustained release calcineurin inhibitors for the prevention of graft rejection | ||||
Key People / Management
Gary Ransom -- Board Member and former CEO
Thomas J Smith -- Chairman ; Chief Executive Officer
Meredith Blake
Amanda Malone -- VP and COO
John Moss
Lisa Portscher
William H Slattery
Sally J Smith
Robyn Willis -- Director of Regulatory Affairs and Preclinical Development
Thomas J Smith -- Chairman ; Chief Executive Officer
Meredith Blake
Amanda Malone -- VP and COO
John Moss
Lisa Portscher
William H Slattery
Sally J Smith
Robyn Willis -- Director of Regulatory Affairs and Preclinical Development
